Relay TherapeuticsRLAY
RLAY
About: Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
Employees: 259
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
274% more call options, than puts
Call options by funds: $483K | Put options by funds: $129K
46% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 24
28% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 58
4% more funds holding
Funds holding: 199 [Q4 2024] → 207 (+8) [Q1 2025]
1.95% less ownership
Funds ownership: 97.95% [Q4 2024] → 96.0% (-1.95%) [Q1 2025]
33% less funds holding in top 10
Funds holding in top 10: 6 [Q4 2024] → 4 (-2) [Q1 2025]
37% less capital invested
Capital invested by funds: $676M [Q4 2024] → $427M (-$249M) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$4
24%
upside
Avg. target
$7
117%
upside
High target
$10
211%
upside
2 analyst ratings
1 positive
50%
1 neutral
50%
0 negative
0%
Guggenheim Michael Schmidt | 211%upside $10 | Buy Maintained | 7 May 2025 |
Wells Fargo | 24%upside $4 | Equal-Weight Initiated | 17 Apr 2025 |
Financial journalist opinion
Based on 4 articles about RLAY published over the past 30 days
Neutral
GlobeNewsWire
3 days ago
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company's Board of Directors, effective June 9, 2025.
Neutral
GlobeNewsWire
1 week ago
Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025
Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer
Neutral
GlobeNewsWire
2 weeks ago
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in two upcoming fireside chats in June: Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 8:45 a.m.
Positive
Zacks Investment Research
3 weeks ago
What Makes Relay Therapeutics (RLAY) a New Buy Stock
Relay Therapeutics (RLAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
GlobeNewsWire
1 month ago
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in two upcoming fireside chats:
Neutral
GlobeNewsWire
1 month ago
Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates
Cash runway extended into 2029 Initiation of Phase 3 ReDiscover-2 trial on track for mid-2025 Initiated Phase 1 RLY-2608 vascular malformations clinical trial in Q1 Extended cash runway expected to fully fund the Company meaningfully past topline data for ReDiscover-2 trial and through clinical proof-of-concept data in Vascular Malformations Approximately $710 million in cash, cash equivalents and investments at end of Q1 2025 CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported first quarter 2025 financial results and corporate updates.
Neutral
GlobeNewsWire
1 month ago
Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025
CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report first quarter 2025 financial results and corporate highlights after the U.S. financial markets close on Monday, May 5, 2025.
Positive
Zacks Investment Research
1 month ago
Top Cancer Stocks to Buy to Boost Your Portfolio's Health
If the cancer space appeals to you, it's time to consider stocks like Pyxis Oncology, Verastem Oncology and Relay Therapeutics.
Positive
Seeking Alpha
2 months ago
Relay Therapeutics: Trying To Find That Right Price
Relay Therapeutics' pipeline has shifted, with the FGFR2 inhibitor lirafugratinib outlicensed to Elevar, bringing in cash and royalties, but losing global rights. RLY-2608, a PI3K-alpha inhibitor, shows promise in breast cancer trials, with plans for a phase 3 trial and potential in other cancers. Financially, RLAY holds $124.3M in cash and $657M in investments, with a cash runway into mid-2026, bolstered by recent cost-saving measures.
Positive
Zacks Investment Research
3 months ago
Down -31.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Relay Therapeutics (RLAY)
The heavy selling pressure might have exhausted for Relay Therapeutics (RLAY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Charts implemented using Lightweight Charts™